[{"address1": "Nihonbashi Mitsui Tower", "address2": "Reception12F 1-1 Nihonbashi-Muromachi 2-chome", "city": "Chuo", "zip": "103-8324", "country": "Japan", "phone": "81 3 3281 6611", "fax": "81 3 3281 6607", "website": "https://www.chugai-pharm.co.jp", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Polivy, Tecentriq, and Phesgo; Neutrogin and Sigmart; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; and research and license agreement with Gero PTE. LTD. to develop novel therapies for age-related diseases. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.", "fullTimeEmployees": 5026, "companyOfficers": [{"maxAge": 1, "name": "Dr. Osamu  Okuda", "age": 61, "title": "President, CEO & Chairman", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 1812414, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Iwaaki  Taniguchi", "age": 58, "title": "Executive VP, Head of Finance Supervisory Division, CFO & Director", "yearBorn": 1966, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Toshiya  Sasai", "title": "Executive of Investor Relations Group & Corporate Communications Department", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kaori  Ouchi", "title": "EVP and Head of Risk & Compliance Department", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Junichi  Takano", "title": "Head of Marketing & Sales Division", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Shinji  Hidaka", "title": "Executive Vice President", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tetsuya  Yamaguchi", "title": "Executive Vice President", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Yoshiyuki  Yano", "title": "Executive Vice President", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kosuke  Iijima", "title": "Head of PHC Solution Department", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tomoyuki  Igawa Ph.D.", "title": "VP & Head of Research Division", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 1, "boardRisk": 8, "compensationRisk": 1, "shareHolderRightsRisk": 2, "overallRisk": 5, "governanceEpochDate": 1764547200, "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://www.chugai-pharm.co.jp/hc/ss/english/ir/index.html", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 50.87, "open": 52.05, "dayLow": 52.05, "dayHigh": 52.18, "regularMarketPreviousClose": 50.87, "regularMarketOpen": 52.05, "regularMarketDayLow": 52.05, "regularMarketDayHigh": 52.18, "dividendRate": 0.67, "dividendYield": 1.21, "exDividendDate": 1767139200, "payoutRatio": 0.44529998, "beta": 0.394, "trailingPE": 35.577923, "forwardPE": 35.577923, "volume": 500, "regularMarketVolume": 500, "averageVolume": 2753, "averageVolume10days": 3080, "averageDailyVolume10Day": 3080, "bid": 51.79, "ask": 56.6, "bidSize": 100, "askSize": 100, "marketCap": 95412510720, "fiftyTwoWeekLow": 32.25, "fiftyTwoWeekHigh": 72.3, "allTimeHigh": 124.75, "allTimeLow": 6.32, "priceToSalesTrailing12Months": 0.07861209, "fiftyDayAverage": 49.9121, "twoHundredDayAverage": 48.788086, "trailingAnnualDividendRate": 107.0, "trailingAnnualDividendYield": 2.103401, "currency": "USD", "tradeable": false, "enterpriseValue": -791390126080, "profitMargins": 0.32723, "floatShares": 639767728, "sharesOutstanding": 1645703327, "heldPercentInsiders": 0.59911996, "heldPercentInstitutions": 0.17982, "impliedSharesOutstanding": 1741421974, "bookValue": 7.3814673, "priceToBook": 7.4226437, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "earningsQuarterlyGrowth": 0.016, "netIncomeToCommon": 397161005056, "trailingEps": 1.54, "forwardEps": 1.54, "lastSplitFactor": "3:1", "lastSplitDate": 1593388800, "enterpriseToRevenue": -0.652, "enterpriseToEbitda": -1.366, "52WeekChange": 0.29221702, "SandP52WeekChange": 0.13613915, "lastDividendValue": 0.866, "lastDividendDate": 1750982400, "quoteType": "EQUITY", "currentPrice": 54.79, "recommendationKey": "none", "totalCash": 882447024128, "totalCashPerShare": 536.212, "ebitda": 579513024512, "totalDebt": 0, "quickRatio": 4.623, "currentRatio": 5.675, "totalRevenue": 1213712957440, "revenuePerShare": 737.545, "returnOnAssets": 0.16259001, "returnOnEquity": 0.21518, "grossProfits": 843281006592, "freeCashflow": 318234492928, "operatingCashflow": 409567002624, "earningsGrowth": 0.016, "revenueGrowth": 0.055, "grossMargins": 0.69478995, "ebitdaMargins": 0.47747, "operatingMargins": 0.46967998, "financialCurrency": "JPY", "symbol": "CHGCF", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "regularMarketChangePercent": 7.7059207, "regularMarketPrice": 54.79, "corporateActions": [{"header": "Dividend", "message": "CHGCF announced a cash dividend of 125.00 with an ex-date of Dec. 31, 2025", "meta": {"eventType": "DIVIDEND", "dateEpochMs": 1767157200000, "amount": "125.00"}}], "regularMarketTime": 1765486800, "exchange": "PNK", "messageBoardId": "finmb_685347", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "shortName": "CHUGAI PHARMACEUTICAL CO", "longName": "Chugai Pharmaceutical Co., Ltd.", "marketState": "CLOSED", "hasPrePostMarketData": false, "firstTradeDateMilliseconds": 1344000600000, "regularMarketChange": 3.920002, "regularMarketDayRange": "52.05 - 52.18", "fullExchangeName": "OTC Markets OTCPK", "averageDailyVolume3Month": 2753, "fiftyTwoWeekLowChange": 22.54, "fiftyTwoWeekLowChangePercent": 0.69891477, "fiftyTwoWeekRange": "32.25 - 72.3", "fiftyTwoWeekHighChange": -17.510002, "fiftyTwoWeekHighChangePercent": -0.24218535, "fiftyTwoWeekChangePercent": 29.221703, "dividendDate": 1504224000, "earningsTimestamp": 1769720400, "earningsTimestampStart": 1769720400, "earningsTimestampEnd": 1769720400, "earningsCallTimestampStart": 1761296400, "earningsCallTimestampEnd": 1761296400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": 1.54, "epsForward": 1.54, "fiftyDayAverageChange": 4.877899, "fiftyDayAverageChangePercent": 0.09772979, "twoHundredDayAverageChange": 6.001915, "twoHundredDayAverageChangePercent": 0.1230201, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "displayName": "Chugai Pharmaceutical", "trailingPegRatio": 4.6687, "__fetch_time": "2025-12-13"}]